SiBone (SIBN) to Release Earnings on Monday

Key Points

• SiBone (NASDAQ:SIBN) is set to release its Q2 2025 earnings after the market closes on August 4th, with analysts expecting a loss of ($0.19) per share and revenue of $48.12 million.
• In the previous quarter, SiBone reported earnings of ($0.15) per share, exceeding estimates, with revenue of $47.29 million.
• Analysts have set new price targets for SiBone, with Needham & Company rating it a "buy" and setting a target at $24.00, while Cantor Fitzgerald issued a target of $25.00.

SiBone (NASDAQ:SIBN - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Monday, August 4th. Analysts expect SiBone to post earnings of ($0.19) per share and revenue of $48.12 million for the quarter. SiBone has set its FY 2025 guidance at EPS.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. On average, analysts expect SiBone to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SiBone Stock Performance

SiBone stock traded down $0.75 during mid-day trading on Thursday, reaching $17.05. The company's stock had a trading volume of 158,141 shares, compared to its average volume of 415,021. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The business has a 50 day moving average price of $17.95 and a 200-day moving average price of $16.61. The firm has a market cap of $726.84 million, a price-to-earnings ratio of -26.62 and a beta of 0.93.

Insiders Place Their Bets

In other SiBone news, Director Jeffrey W. Dunn sold 3,377 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the completion of the sale, the director directly owned 17,354 shares in the company, valued at $330,593.70. This represents a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 4,147 shares of SiBone stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $19.56, for a total value of $81,115.32. Following the transaction, the insider directly owned 282,015 shares in the company, valued at approximately $5,516,213.40. The trade was a 1.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,366 shares of company stock valued at $1,861,774. 4.00% of the stock is currently owned by insiders.

Institutional Trading of SiBone

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new position in SiBone during the first quarter valued at about $225,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company's stock valued at $343,000 after purchasing an additional 1,053 shares during the period. Jane Street Group LLC bought a new stake in SiBone during the first quarter worth about $1,818,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock worth $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SIBN. Truist Financial increased their price target on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of SiBone in a research note on Tuesday, May 6th.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.